Our top pick for
Eltek Ltd is an electronic components business based in the US. Eltek shares (ELTK) are listed on the NASDAQ and all prices are listed in US Dollars. Eltek employs 286 staff and has a trailing 12-month revenue of around USD$35.8 million.
|52-week range||USD$2.28 - USD$8.12|
|50-day moving average||USD$5.8736|
|200-day moving average||USD$5.1112|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.505|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Eltek stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eltek's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eltek's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Eltek shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Eltek's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$4 million.
The EBITDA is a measure of a Eltek's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$35.8 million|
|Operating margin TTM||6.81%|
|Gross profit TTM||USD$6 million|
|Return on assets TTM||6.6%|
|Return on equity TTM||31.42%|
|Market capitalisation||USD$31.7 million|
TTM: trailing 12 months
There are currently 2,804 Eltek shares held short by investors – that's known as Eltek's "short interest". This figure is 49.7% down from 5,575 last month.
There are a few different ways that this level of interest in shorting Eltek shares can be evaluated.
Eltek's "short interest ratio" (SIR) is the quantity of Eltek shares currently shorted divided by the average quantity of Eltek shares traded daily (recently around 40057.142857143). Eltek's SIR currently stands at 0.07. In other words for every 100,000 Eltek shares traded daily on the market, roughly 70 shares are currently held short.
However Eltek's short interest can also be evaluated against the total number of Eltek shares, or, against the total number of tradable Eltek shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eltek's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Eltek shares in existence, roughly 0 shares are currently held short) or 0.0009% of the tradable shares (for every 100,000 tradable Eltek shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eltek.
Find out more about how you can short Eltek stock.
We're not expecting Eltek to pay a dividend over the next 12 months.
Eltek's shares were split on a 1:5 basis on 22 November 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eltek shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Eltek shares which in turn could have impacted Eltek's share price.
Over the last 12 months, Eltek's shares have ranged in value from as little as $2.28 up to $8.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eltek's is -2.7172. This would suggest that Eltek's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Eltek has bucked the trend.
Eltek Ltd. manufactures, markets, and sells printed circuit boards (PCBs) in Israel, Europe, North America, India, the Netherlands, and internationally. The company offers a range of custom designed PCBs, including rigid, double-sided, and multi-layer PCBs; and flexible circuitry, such as flex and flex-rigid boards. It primarily serves manufacturers of defense and aerospace, medical, industrial, telecom, and networking equipment, as well as contract electronic manufacturers and others. The company markets and sells its products primarily through direct sales personnel, sales representatives, and PCB trading and manufacturing companies. Eltek Ltd. was founded in 1970 and is headquartered in Petach Tikva, Israel. Eltek Ltd. is a subsidiary of Nistec Golan Ltd.
Everything we know about the Reddit IPO, plus information on how to buy in.
Everything we know about the Hayward Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Alignment Healthcare Inc IPO, plus information on how to buy in.
Everything we know about the Olink Holding AB (publ) IPO, plus information on how to buy in.
Everything we know about the Procore IPO, plus information on how to buy in.
Everything we know about the Navios South American Logistics Inc IPO, plus information on how to buy in.
Everything we know about the Lava Therapeutics IPO, plus information on how to buy in.
Everything we know about the Pop Culture Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Bukalapak IPO, plus information on how to buy in.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.